Siemens Healthineers divesting diagnostics division by 2030 or spinning off post restructuring the division is a possibility, however, it has not spoken yet to any of the potential suitors.
It is indeed possible that the diagnostics business is no longer going to be part of the medical technology group in 2030 if it is suggested that this is going to be better for the division, said Bernd Montag, the CEO, at a press briefing on the sidelines of its capital markets day on November 19, 2025.
For its financial years between 2027 and the end of September 2030, Healthineers happens to be targeting a yearly revenue growth of between 6% and 9% coming from its other two divisions put together, which are the Imaging and Precision Therapy divisions, while the diagnostics arm is anticipated to enhance towards growth in the mid-single-digit percentages.
The yearly U.S. tariff burden of almost 400 million euros, which is equivalent to $464 million, should be totally offset by 2028, all thanks to the elevated productivity as well as higher prices, said Jochen Schmitz, the finance chief.
Parent Siemens went on to say recently that it would go ahead and shrink its €33.5 billion stake in Healthineers by way of transferring shares within the medical equipment maker to its own shareholders.
Apparently, with Siemens Healthineers divesting diagnostics division, the transfer would lead to the German engineering group slashing its 67% stake to 37% or even less, with Siemens stressing trains and automation technology when it comes to factories and buildings.
Notably, Siemens could also further decrease its holding to less than 20%, especially in the medium term, the company added.
